Targets › B7H4
2 programs from 2 companies in 5 trials: 2 Phase 3, 2 Phase 1, 1 Phase 2; Oncology; next expected readout Mar 2027.
Negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. When expressed on the cell surface of tumor macrophages, plays an important role, together with regulatory T-cells (Treg), in the suppression of tumor-associated antigen-specific T-cell immunity. (UniProt, Q7Z7D3)
Open in Phaseline: the race on B7H4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Hansoh BioMedical R&D Company | HS-20089 Anti-B7-H4 antibody-drug conjugate with topoisomerase I inhibitor payload | B7H4 | Phase 3 | Ovarian Cancer; Advanced Solid Tumors | Mar 2027 |
| AstraZeneca | Puxitatug Samrotecan (AZD8205) B7-H4-targeted antibody-drug conjugate (ADC) | B7H4 | Phase 3 | Endometrial Cancer; Breast Cancer | Sep 2027 |
Ovarian Cancer (2) Advanced Solid Tumors (1) Endometrial Cancer (1) Breast Cancer (1)
small molecule (1), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.